Pancreatic Cancer Research

ResearcherShanghai Jiao Tong UniversityNo recent work listed

Hai Xia Hu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-4759-9730; OpenAlex author ID A5082320561. Sources: OpenAlex.

Their work

Papers
13 (first author 4, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
21
Papers, trials and grants by year

2014: 1 paper · 2015: 2 papers · 2016: 5 papers · 2017: 2 papers · 2018: 2 papers · 2019: 1 paper

Papers 13

  1. JQ1 effectively inhibits vasculogenic mimicry of pancreatic ductal adenocarcinoma cells via the ERK1/2-MMP-2/9 signaling pathway both in vitro and in vivo. Co-author PMID 30899402↗
  2. Synergistic effects of the combination of 5-Aza‑CdR and suberoylanilide hydroxamic acid on the anticancer property of pancreatic cancer. Co-author DOI 10.3892/or.2017.6059↗
  3. High expression of TGR5 predicts a poor prognosis in patients with pancreatic cancer. Co-author PMID 31949735↗
  4. Elevated COX-2 Expression Promotes Angiogenesis Through EGFR/p38-MAPK/Sp1-Dependent Signalling in Pancreatic Cancer. Co-author DOI 10.1038/s41598-017-00288-4↗
  5. Correlated high expression of FXR and Sp1 in cancer cells confers a poor prognosis for pancreatic cancer: A study based on TCGA and tissue microarray. Co-author DOI 10.18632/oncotarget.16633↗
  6. The M2 phenotype of tumor-associated macrophages in the stroma confers a poor prognosis in pancreatic cancer. Co-author DOI 10.1007/s13277-015-4741-z↗
  7. Simultaneous high expression of PLD1 and Sp1 predicts a poor prognosis for pancreatic ductal adenocarcinoma patients. First author DOI 10.18632/oncotarget.12447↗
  8. EZH2 promotes cell migration and invasion but not alters cell proliferation by suppressing E-cadherin, partly through association with MALAT-1 in pancreatic ca… Co-author DOI 10.18632/oncotarget.7156↗
  9. Aberrant expression of nuclear HDAC3 and cytoplasmic CDH1 predict a poor prognosis for patients with pancreatic cancer. First author DOI 10.18632/oncotarget.7663↗
  10. Sp1 and COX2 expression is positively correlated with a poor prognosis in pancreatic ductal adenocarcinoma. First author DOI 10.18632/oncotarget.8593↗
  11. Suppressed expression of LDHB promotes pancreatic cancer progression via inducing glycolytic phenotype. Co-author DOI 10.1007/s12032-015-0589-8↗
  12. Functional significance of macrophages in pancreatic cancer biology. Co-author DOI 10.1007/s13277-015-4127-2↗
  13. Histone deacetylase 3 promotes pancreatic cancer cell proliferation, invasion and increases drug-resistance through histone modification of P27, P53 and Bax. First author DOI 10.3892/ijo.2014.2568↗

Closest collaborators

The 21 strongest of 21 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Feng Jiao · 11 shared papers, 2014–2019 · strength 0.77
  2. Ting Han · 9 shared papers, 2015–2019 · strength 0.68
  3. Liwei Wang · 9 shared papers, 2014–2017 · strength 0.55
  4. Meng Zhuo · 7 shared papers, 2016–2019 · strength 0.54
  5. Lei Wang · 5 shared papers, 2014–2017 · strength 0.31
  6. Liwei Wang · 3 shared papers, 2015–2019 · strength 0.28
  7. Jiujie Cui · 3 shared papers, 2015–2019 · strength 0.23
  8. Junjie Hang · 3 shared papers, 2016 · strength 0.19
  9. Leilei Wu · 2 shared papers, 2017 · strength 0.14
  10. Haiyan Yang · 2 shared papers, 2016 · strength 0.12
  11. Ruyi Zhao · 1 shared paper, 2018 · strength 0.08
  12. Qian Huang · 1 shared paper, 2018 · strength 0.08
  13. Jin Quan Cheng · 1 shared paper, 2018 · strength 0.08
  14. Lixia Wu · 1 shared paper, 2017 · strength 0.07
  15. Weifeng Song · 1 shared paper, 2016 · strength 0.06
  16. Jiong Hu · 1 shared paper, 2016 · strength 0.06
  17. Yangyang Zhou · 1 shared paper, 2016 · strength 0.06
  18. Junjie Huang · 1 shared paper, 2016 · strength 0.06
  19. Ming Quan · 1 shared paper, 2015 · strength 0.05
  20. Weihua Jiang · 1 shared paper, 2015 · strength 0.05
  21. Lei Wang · 1 shared paper, 2015 · strength 0.05

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.